Overall, the data suggest that IGF2BP1 protein can be considered to be a moderately tumor-enriched biomarker in EAC, but it may only be useful as a therapeutic target or diagnostic biomarker in a limited proportion of patients. Here, IGF2BP1 is linked to neoplasm.